Back to All

Diaceutics appoints Ken Ruppel as VP of Scientific and Medical Services

5 February, 2024

Diaceutics appoints Ken Ruppel as VP of Scientific and Medical Services 


Belfast and London, 5 February- a leading technology and solutions provider to pharma and biotech companies, is pleased to announce the appointment of Ken Ruppel as Vice President of Scientific & Medical Services, effective February 1st, 2024.

With a commitment to ensuring every patient has access to the right treatment at the right time, Diaceutics welcomes Ken to lead the expansion of current offerings and development of innovative solutions in precision medicine.

Ken joins Diaceutics with an impressive background of over 25 year’s experience delivering commercial and operational success in the medical research, life sciences, pharmaceutical, biotechnology and clinical diagnostic markets. Having most recently served as VP of Precision Medicine at Amplity Health, where he played a pivotal role in supporting the launch of over 20 companion diagnostic indications across diverse tumour types and laboratory methodologies in the US. His strategic expertise was instrumental in guiding Precision Medicine strategies and tactics for 12 pharmaceutical brands and his impressive track record showcases his dedication to advancing precision medicine initiatives.

In his role at Diaceutics, Ken will lead the identification, development and support of strategic growth opportunities within Scientific & Medical products and services. His responsibilities will include driving innovation and leading client interactions.

Ken’s passion and expertise in diagnostic enabled therapies will play a significant role in realizing the company’s core mission – making precision medicine globally accessible through the DXRX platform.

Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, commented:

"We are extremely pleased to welcome Ken to Diaceutics as our VP Scientific and Medical Services. His proven track record in Precision Medicine aligns seamlessly with our vision, and we are confident in his ability to lead our Scientific and Medical team to be a driving force towards success.”

For media enquiries contact:

Diaceutics PLC Tel: +44 (0)28 9040 6500

Cathy Magovern

Corporate Marketing & Communications Director               [email protected]


About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network ®

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny